InsidersTradesSigma
Track the 华仁药业 stock price and the full management transaction log of the company, a listed equity based in China. Shares are quoted on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 华仁药业 has logged 9 insider filings. Market capitalisation: €3.2bn. The latest transaction was reported on 6 February 2024 (Purchase). Among the most active insiders: 杨效东. All data is free.
9
Insider Decl.
n/a
Thresholds
€574,067
9 ops.
Buy Volume
n/a
n/a
Sell Volume
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,526 of 29,062 companies
35.4
score / 100
Value48
Quality23
FCF yld11%
Earn yld-15%
EV/EBITDA·
ROE-40%
Gross mgn37%
Net mgn-35%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 February 2024
Declarations9 total
9 of 9 declarations
About 华仁药业
Hua Ren Pharmaceutical is a company in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the development and production of innovative drugs.